1.	Phase I/II Study of GTI-2040 and Capecitabine in Patients With Advanced or Metastatic Renal Cell Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LORUS-L01-1409, NCT00056173
2.	Phase II Study of GTI-2040 and Docetaxel in Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors (Phase I study closed to accrual as of 8/5/2004) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-017, NCI-6104, NCT00074022, 6104
3.	Phase II Study of GTI-2040, Docetaxel, and Prednisone in Patients With Hormone-Refractory Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-024, NCI-6102, 6102, NCT00087165
4.	Combination of GTI 2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) Phase: Phase II Type: Treatment Status: Completed Age: 18 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: 2040AML201, NCT00565058
5.	GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000327757, CCC-PHII-46, UCD-200311533-1, CHNMC-PHII-46, NCI-6093, 6093, NCT00068588
6.	Phase I Study of GTI-2040 and High-Dose Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: OSU-0304, OSU-20030030, NCI-6108, NCT00070551, 6108
7.	Phase I Study of GTI-2040 and Gemcitabine in Patients With Metastatic or Unresectable Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CTRC-IDD-0306, NCI-6090, NCT00078962, 6090
8.	GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000365466, U01CA062505, P30CA033572, CCC-PHI-41, CHNMC-PHI-41, NCI-6099, 6099, NCT00084643
9.	GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000539257, U01CA062505, P30CA033572, CCC-PHI-57, 7689, PHI-57, NCT00459212